Validated LC-MS/MS Method for Simultaneous Quantitation of Enasidenib and its Active Metabolite, AGI-16903 in Small Volume Mice Plasma: Application to a Pharmacokinetic Study

Abstract

Enasidenib is a selective mutant isocitrate dehydrogenase 2 inhibitor approved for the treatment of relapsed and refractory acute myeloid leukemia patients. A sensitive and rapid method has been developed and validated as per regulatory guideline for the simultaneous quantitation of enasidenib and its active metabolite, AGI-16903 in mice plasma using an LC-MS/MS. Enasidenib and AGI-16903 along with internal standard were extracted from mice plasma using simple protein precipitation method. Chromatographic resolution of enasidenib, AGI-16903 and the internal standard (close analogue of AGI-16903) was achieved on a Chromolith RP-18e column using 0.2% formic acid:acetonitrile (15:85, v/v) as an eluent, which was delivered at a flow-rate of 1.2 mL/min. The MS/MS ion transitions monitored were m/z 474.1→267.2, 402.1→188.1 and 421.0→146.1 for enasidenib, AGI-16903 and the internal standard, respectively. The linearity range was 1.01–3023 ng/mL for both enasidenib and AGI-16903. The within-run and between-run accuracy and within-run and between-run precision were in the range of − 2.29 to 2.72 (as one value is in negative side). and 4.65–9.82%, respectively for enasidenib; 0.19–10.3 and 3.22–9.22%, respectively for AGI-16903. Both enasidenib and AGI-16903 were found to be stable in stability (up to three freeze-thaw cycles and for long-term at −80°C for 30 days) and processed (bench-top for 6 h and in in-injector for 24 h) samples. Application of the validated method was shown in a pharmacokinetic study in mice.

Key words

enasidenib - AGI-16903 - mice plasma - LC-MS/MS - method validation - pharmacokinetics

• References

• 1 Siegel RL, Miller KD, Jemal A. Cancer statistics, 2018. CA Cancer J Clin 2018; 68: 7-30
• 2 Abou Dalle I, DiNardo CD. The role of enasidenib in the treatment of mutant IDH2 acute myeloid leukemia. Ther Adv Hematol 2018; 9: 163-173
• 3 Buege MJ, Di Pippo AJ, Di Nardo CD. Evolving treatment strategies for elder leukemia patients with IDH mutations. Cancers 2018; 10: 187
• 4 Idhifa™. Celgene Corporation. Idhifa Prescribing Information August 2017. Available online http://media.celgene.com/content/uploads/idhifa-pi.pdf (accessed on 15 November 2018)
• 5 Yen K, Travins J, Wang F. et al. AG-221, a first-in-class therapy targeting acute myeloid leukemia harboring oncogenic IDH2 mutations. Cancer Discovery 7: 478-493
• 6 Pang NH, Liu Q, Lu XR, Yang SF, Lin DD, Hu GX. Determination and pharmacokinetic study of enasidenib in rat plasma by UPLC-MS/MS. J Pharm Biomed Analy 2018; 157: 165-170
• 7 Dittakavi S, Jat RK, Mullangi R. Quantitative analysis of enasidenib in dried blood spots of mice blood using an increased sensitive LC-MS/MS method: Application to a pharmacokinetic study. Biomed Chromatogr 2019; 33: e4491
• 8 Li Y, Liu L, Gomez D, Chen J, Tong Z, Pamisano M, Zhou S. Pharmacokinetics and safety of enasidenib following single oral doses in Japanese and Caucasian subjects. Pharmacol Res Perspect 2018; 6: e00436
• 9 Jeremy T, Luke U. N,6-bis(aryl or heteroaryl)-1,3,5-triazine-2,4-diamine compounds as IDH2 mutants inhibitors for the treatment of cancer. WO2015006592A1
• 10 US DHHS, FDA, CDER, CVM. Guidance for Industry: Bioanalytical Method Validation. U.S. Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER), Center for Veterinary Medicine (CVM). 2018. Rockville, MD, USA.
• 11 Srinivas NR. Sensitivity enhancement in tandem liquid chromatographic mass spectrometric assays by summation of two transition ion pairs-perspectives. J Sep Sci 2009; 32: 483-486
• 12 Manjunath Swamy J, Kamath N, Radha Shekar AK, Srinivas NR, Kristjansson F. Sensitivity enhancement and matrix effect evaluation during summation of multiple transition pairs-case studies of clopidogrel and ramiprilat. Biomed Chromatogr 2010; 24: 528-534
• 13 Xia YQ, Jemal M. Phospholipids in liquid chromatography/mass spectrometry bioanalysis: comparison of three tandem mass spectrometric techniques for monitoring plasma phospholipids, the effect of mobile phase composition on phospholipids elution and the association of phospholipids with matrix effects. Rapid Commun Mass Spectrom 2009; 23: 2125-2138
• 14 Srinivas NR. Dodging matrix effects in liquid chromatography tandem mass spectrometric assays-compilation of key learnings and perspectives. Biomed Chromatogr 2009; 23: 451-454
• 15 Gabani BB, Todmal U, Saini NK, Balakrishna VA, Sulochana SP, Timmapuram A, Zainuddin M, Balaji N, Shuvranshu P, Srinivas NR, Mullangi R. Stereoselective pharmacokinetics and tissue distribution of levodropropizine after administration of pure levodropropizine and the rac-dropropizine to Sprague-Dawley rats. Xenobiotica 2019 (accepted)